Literature DB >> 15746570

Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.

Sibel Ozyazgan1, Nilüfer Kutluata, Selim Afşar, Sule Beyhan Ozdaş, Ahmet Gökhan Akkan.   

Abstract

We investigated the vascular effects of glucagon-like peptide-1 (GLP-1) and Exendin-4 in type 2 diabetic rat aortae. Studies were performed in a normal control group (NC) (0.2 ml i.p. saline, n = 10), streptozotocin (STZ)/nicotinamide diabetic control group (DC) (a single dose of 80 mg/kg STZ i.p. injection 15 min after administration of 230 mg/kg nicotinamide i.p.), GLP-1 (GLPC) control group (1 microg/kg twice daily i.p. for 1 month, n = 10), Exendin-4 control group (EXC) (0.1 microg/kg twice daily i.p. for 1 month, n = 10), GLP-1-treated diabetic group (GLPT) (1 microg/kg twice daily i.p. for 1 month, n = 10), and Exendin-4-treated diabetic group (EXT) (0.1 microg/kg twice daily i.p. for 1 month, n = 10). One month of GLP-1 and Exendin-4 treatment significantly decreased the blood glucose levels of diabetic rats (113 +/- 2 mg/dl, p < 0.001, and 117 +/- 1 mg/dl, p < 0.001, respectively versus 181 +/- 9 mg/dl in the DC group). Sensitivity (pD2) and maximum response (% Max. Relax) of acetylcholine-stimulated relaxations in the DC group (pD2: 6.73 +/- 0.12 and 55 +/- 6, respectively) were decreased compared with the non-diabetic NC group (pD2: 7.41 +/- 0.25, p < 0.05, and 87 +/- 4, p < 0.01). Treating diabetic rats with GLP-1, pD2 values and with Exendin-4, Max. Relax %values of aortic strips to acetylcholine returned to near non-diabetic NC values (pD2: 7.47 +/- 0.15, p < 0.05, and 87 +/- 3, p < 0.01, respectively). Maximal contractile responses (Emax) to noradrenaline in aortic strips from the diabetic DC group (341 +/- 27 mg tension/mg wet weight) were significantly decreased compared with the non-diabetic NC (540 +/- 66 mg tension/mg wet weight, p < 0.001) and the GLPT group (490 +/- 25 mg tension/mg wet weight, p < 0.05). There were no significant differences in pD2 values of aortic strips to noradrenaline from all groups. Emax to KCl in aortic strips from the DC group (247 +/- 10 mg tension/mg wet weight, p < 0.01) was significantly decreased compared with non-diabetic NC group (327 +/- 26 mg tension/mg wet weight). Treating diabetic rats with GLP-1 (GLPT), Emax values of aortic strips to KCl returned to near non-diabetic NC values (271 +/- 12 mg tension/mg wet weight). GLP-1 and (partially) Exendin-4 treatment could improve the increased blood glucose level and normalize the altered vascular tone in type 2 diabetic rats. 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15746570     DOI: 10.1159/000084277

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  22 in total

Review 1.  Glucagon-like peptide-1 and its cardiovascular effects.

Authors:  Kyung-Sun Heo; Keigi Fujiwara; Jun-ichi Abe
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

2.  Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial.

Authors:  Christian Ott; Iris Kistner; Mirjam Keller; Stefanie Friedrich; Carsten Willam; Peter Bramlage; Roland E Schmieder
Journal:  Diabetologia       Date:  2016-09-01       Impact factor: 10.122

3.  Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.

Authors:  Steven P Moberly; Zachary C Berwick; Meredith Kohr; Mark Svendsen; Kieren J Mather; Johnathan D Tune
Journal:  Exp Biol Med (Maywood)       Date:  2012-02-16

Review 4.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

Review 5.  The cardiovascular effects of GLP-1 receptor agonists.

Authors:  Theodore Okerson; Robert J Chilton
Journal:  Cardiovasc Ther       Date:  2010-12-19       Impact factor: 3.023

6.  Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis.

Authors:  M Marzioni; G Alpini; S Saccomanno; C Candelaresi; J Venter; C Rychlicki; G Fava; H Francis; L Trozzi; A Benedetti
Journal:  Gut       Date:  2008-10-01       Impact factor: 23.059

Review 7.  Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.

Authors:  Paul Stranges; Ujjaini Khanderia
Journal:  Ther Adv Drug Saf       Date:  2012-08

8.  Incretin attenuates diabetes-induced damage in rat cardiac tissue.

Authors:  Eman AbdElmonem Elbassuoni
Journal:  J Physiol Sci       Date:  2014-07-11       Impact factor: 2.781

Review 9.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

Review 10.  Cardiovascular and hemodynamic effects of glucagon-like peptide-1.

Authors:  Adam G Goodwill; Kieren J Mather; Abass M Conteh; Daniel J Sassoon; Jillian N Noblet; Johnathan D Tune
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.